1
|
Cruz PD, Wargowsky R, Gonzalez-Almada A, Sifontes EP, Shaykhinurov E, Jaatinen K, Jepson T, Lafleur JE, Yamane D, Perkins J, Pasquale M, Giang B, McHarg M, Falk Z, McCaffrey TA. Blood RNA Biomarkers Identify Bacterial and Biofilm Coinfections in COVID-19 Intensive Care Patients. J Intensive Care Med 2024:8850666241251743. [PMID: 38711289 DOI: 10.1177/08850666241251743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/08/2024]
Abstract
Purpose: Secondary opportunistic coinfections are a significant contributor to morbidity and mortality in intensive care unit (ICU) patients, but can be difficult to identify. Presently, new blood RNA biomarkers were tested in ICU patients to diagnose viral, bacterial, and biofilm coinfections. Methods: COVID-19 ICU patients had whole blood drawn in RNA preservative and stored at -80°C. Controls and subclinical infections were also studied. Droplet digital polymerase chain reaction (ddPCR) quantified 6 RNA biomarkers of host neutrophil activation to bacterial (DEFA1), biofilm (alkaline phosphatase [ALPL], IL8RB/CXCR2), and viral infections (IFI27, RSAD2). Viral titer in blood was measured by ddPCR for SARS-CoV2 (SCV2). Results: RNA biomarkers were elevated in ICU patients relative to controls. DEFA1 and ALPL RNA were significantly higher in severe versus incidental/moderate cases. SOFA score was correlated with white blood cell count (0.42), platelet count (-0.41), creatinine (0.38), and lactate dehydrogenase (0.31). ALPL RNA (0.59) showed the best correlation with SOFA score. IFI27 (0.52) and RSAD2 (0.38) were positively correlated with SCV2 viral titer. Overall, 57.8% of COVID-19 patients had a positive RNA biomarker for bacterial or biofilm infection. Conclusions: RNA biomarkers of host neutrophil activation indicate the presence of bacterial and biofilm coinfections in most COVID-19 patients. Recognizing coinfections may help to guide the treatment of ICU patients.
Collapse
Affiliation(s)
- Philip Dela Cruz
- Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Richard Wargowsky
- Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Alberto Gonzalez-Almada
- Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Erick Perez Sifontes
- Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Eduard Shaykhinurov
- Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Kevin Jaatinen
- Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Tisha Jepson
- Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
- True Bearing Diagnostics, Washington, DC, USA
| | - John E Lafleur
- Department of Emergency Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - David Yamane
- Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - John Perkins
- Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Mary Pasquale
- Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Brian Giang
- Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Matthew McHarg
- Department of Anesthesiology and Critical Care Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Zach Falk
- Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
| | - Timothy A McCaffrey
- Department of Medicine, Division of Genomic Medicine, The George Washington University Medical Center, Washington, DC, USA
- True Bearing Diagnostics, Washington, DC, USA
- Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University Medical Center, Washington, DC, USA
| |
Collapse
|
2
|
Han JK, Perkins J, Lerner D, Yim MT, Ishii LE. Comparison of nasal valve dysfunction treatment outcomes for temperature-controlled radiofrequency and functional rhinoplasty surgery: a systematic review and meta-analyses. Rhinology 2024:3151. [PMID: 38217624 DOI: 10.4193/rhinrhin23.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2024]
Abstract
BACKGROUND Nasal valve dysfunction (NVD) is a substantial contributor to nasal airway obstruction. Minimally-invasive temp-erature-controlled radiofrequency (TCRF) treatment of the nasal valve is available and comparison with surgical techniques is warranted. METHODOLOGY Databases: Medline (PubMed), Embase, Cochrane Library. POPULATION adults with preprocedural nasal obstruction symptom evaluation (NOSE) score ≥45. Treatment effects were derived from a random effects model and reported as weighted mean difference in NOSE score between baseline; 3, 6, and 12 months postprocedure. RESULTS Of 2529 initial articles, 5 studies describing TCRF treatment and 63 studies describing functional rhinoplasty were included. Pooled effect sizes for TCRF treatment and functional rhinoplasty were comparable in all analyses. CONCLUSIONS TCRF treatment of the internal nasal valve for NVD was associated with sustained effects comparable to functional rhinoplasty addressing the nasal valve only, rhinoplasty without concomitant turbinate treatment, and all rhinoplasty.
Collapse
Affiliation(s)
- J K Han
- Department of Otolaryngology - Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA
| | - J Perkins
- Independent Clinical Researcher, Sunnyvale, CA, USA
| | - D Lerner
- Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - M T Yim
- Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health, Shreveport, LA, USA
| | - L E Ishii
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
3
|
Han JK, Perkins J, Lerner D, Yim MT, Ishii LE. Comparison of nasal valve dysfunction treatment outcomes for temperature-controlled radiofrequency and functional rhinoplasty surgery: a systematic review and meta-analyses. Rhinology 2024; 0:3151. [PMID: 38217624 DOI: 10.4193/rhin23.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2024]
Abstract
BACKGROUND Nasal valve dysfunction (NVD) is a substantial contributor to nasal airway obstruction. Minimally-invasive temp-erature-controlled radiofrequency (TCRF) treatment of the nasal valve is available and comparison with surgical techniques is warranted. METHODOLOGY Databases: Medline (PubMed), Embase, Cochrane Library. POPULATION adults with preprocedural nasal obstruction symptom evaluation (NOSE) score ≥45. Treatment effects were derived from a random effects model and reported as weighted mean difference in NOSE score between baseline; 3, 6, and 12 months postprocedure. RESULTS Of 2529 initial articles, 5 studies describing TCRF treatment and 63 studies describing functional rhinoplasty were included. Pooled effect sizes for TCRF treatment and functional rhinoplasty were comparable in all analyses. CONCLUSIONS TCRF treatment of the internal nasal valve for NVD was associated with sustained effects comparable to functional rhinoplasty addressing the nasal valve only, rhinoplasty without concomitant turbinate treatment, and all rhinoplasty.
Collapse
Affiliation(s)
- J K Han
- Department of Otolaryngology - Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA
| | - J Perkins
- Independent Clinical Researcher, Sunnyvale, CA, USA
| | - D Lerner
- Department of Otolaryngology - Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - M T Yim
- Department of Otolaryngology - Head and Neck Surgery, Louisiana State University Health, Shreveport, LA, USA
| | - L E Ishii
- Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| |
Collapse
|
4
|
Perkins J, Grogan C. M221 FOOD PROTEIN-INDUCED ENTEROCOLITIS SYNDROME MASQUERADING AS INTUSSUSCEPTION. Ann Allergy Asthma Immunol 2021. [DOI: 10.1016/j.anai.2021.08.350] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
5
|
Rudsenske N, Perkins J. M225 INCIDENTAL FINDING OF LOW SERUM IGA IN TYPE 1 DIABETES MELLITUS REVEALS DIAGNOSIS OF CVID. Ann Allergy Asthma Immunol 2020. [DOI: 10.1016/j.anai.2020.08.253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
6
|
Bauers SR, Holder A, Sun W, Melamed CL, Woods-Robinson R, Mangum J, Perkins J, Tumas W, Gorman B, Tamboli A, Ceder G, Lany S, Zakutayev A. Ternary nitride semiconductors in the rocksalt crystal structure. Proc Natl Acad Sci U S A 2019; 116:14829-14834. [PMID: 31270238 PMCID: PMC6660719 DOI: 10.1073/pnas.1904926116] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Inorganic nitrides with wurtzite crystal structures are well-known semiconductors used in optical and electronic devices. In contrast, rocksalt-structured nitrides are known for their superconducting and refractory properties. Breaking this dichotomy, here we report ternary nitride semiconductors with rocksalt crystal structures, remarkable electronic properties, and the general chemical formula Mgx TM 1-xN (TM = Ti, Zr, Hf, Nb). Our experiments show that these materials form over a broad metal composition range, and that Mg-rich compositions are nondegenerate semiconductors with visible-range optical absorption onsets (1.8 to 2.1 eV) and up to 100 cm2 V-1⋅s-1 electron mobility for MgZrN2 grown on MgO substrates. Complementary ab initio calculations reveal that these materials have disorder-tunable optical absorption, large dielectric constants, and electronic bandgaps that are relatively insensitive to disorder. These ternary Mgx TM 1-xN semiconductors are also structurally compatible both with binary TMN superconductors and main-group nitride semiconductors along certain crystallographic orientations. Overall, these results highlight Mgx TM 1-xN as a class of materials combining the semiconducting properties of main-group wurtzite nitrides and rocksalt structure of superconducting transition-metal nitrides.
Collapse
Affiliation(s)
- Sage R Bauers
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401;
| | - Aaron Holder
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401
- Department of Chemical and Biological Engineering, University of Colorado, Boulder, Boulder, CO 80309
| | - Wenhao Sun
- Materials Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720
| | - Celeste L Melamed
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401
- Department of Physics, Colorado School of Mines, Golden, CO 80401
| | - Rachel Woods-Robinson
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401
- Materials Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720
- Applied Science and Technology Graduate Group, University of California, Berkeley, CA 94720
| | - John Mangum
- Department of Metallurgical and Materials Engineering, Colorado School of Mines, Golden, CO 80401
| | - John Perkins
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401
| | - William Tumas
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401
| | - Brian Gorman
- Department of Metallurgical and Materials Engineering, Colorado School of Mines, Golden, CO 80401
| | - Adele Tamboli
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401
| | - Gerbrand Ceder
- Materials Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720
- Department of Materials Science and Engineering, University of California, Berkeley, CA 94720
| | - Stephan Lany
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401
| | - Andriy Zakutayev
- Materials Science Center, National Renewable Energy Laboratory, Golden, CO 80401;
| |
Collapse
|
7
|
Cuffolo G, Hardy E, Perkins J, Hands LJ. The effects of foam sclerotherapy on ulcer healing: a single-centre prospective study. Ann R Coll Surg Engl 2019; 101:285-289. [PMID: 30602297 PMCID: PMC6432956 DOI: 10.1308/rcsann.2018.0218] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/04/2018] [Indexed: 11/22/2022] Open
Abstract
INTRODUCTION This prospective study of foam sclerotherapy for varicose veins aimed to determine the outcomes of treatment including ulcer healing and complication rates in our unit. Data were collected prospectively over a 10-year period and maintained on a database by our vascular sciences unit, which performed the planning and post-treatment venous duplex scans. Patients undergoing treatment due to venous ulceration were identified from this database. An initial cohort of patients underwent a follow-up scan and assessment at one year. MATERIALS AND METHODS Patients were treated with foam sclerotherapy, in multiple sessions if required, to occlude all incompetent superficial veins greater than 3 mm in size. We used 3% sodium tetradecyl sulphate as our sclerosing agent, according to our departmental protocol, followed by a period of compression therapy. Patients underwent pre- and post-treatment scans to assess venous competence, the effects of treatment and any complications that arose. RESULTS We identified 336 patients treated for clinical, aetiological, anatomical and pathophysiological stage 5/6 venous ulceration. At six weeks post-treatment, 21% had fully healed ulcers and a further 46.1% were clinically improving with no further venous incompetence. The remainder continued treatment. An initial cohort of 162 patients was assessed at one year and 77.1% ulcers remained healed. The remainder demonstrated some venous incompetence and ultimately 12.5% required further treatment. Our complication rates were similar to those quoted in published meta-analyses including a deep vein thrombosis rate of 1.16%. CONCLUSIONS Foam sclerotherapy remains a useful treatment option for venous ulceration with a low morbidity rate.
Collapse
Affiliation(s)
- G Cuffolo
- Department of Vascular Surgery, Oxford University Hospitals, Oxford, UK
- Department of General Surgery, Wexham Park Hospital, Wexham, Slough, UK
| | - E Hardy
- Department of Vascular Surgery, Oxford University Hospitals, Oxford, UK
| | - J Perkins
- Department of Vascular Surgery, Oxford University Hospitals, Oxford, UK
| | - LJ Hands
- Department of Vascular Surgery, Oxford University Hospitals, Oxford, UK
- Nuffield Department of Surgery, University of Oxford, Oxford, UK
| |
Collapse
|
8
|
Perkins J, Yates A, Schmidt L. SELECTIVE IGA DEFICIENCY IN A WILLIAMS SYNDROME PATIENT, AN UNCOMMON PRESENTATION OF A COMMON DIAGNOSIS. Ann Allergy Asthma Immunol 2018. [DOI: 10.1016/j.anai.2018.09.313] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
9
|
Calimlim A, Zemple R, Perkins J, Saccocci M, Dane F, Bernier C, Rose-Inman H, Glick R. 254 Timing Impact of Out-of-Hospital Intravenous Fluids in Sepsis. Ann Emerg Med 2018. [DOI: 10.1016/j.annemergmed.2018.08.259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
10
|
Paepke S, Wilhelm OG, Schmitt M, Noske A, Schricker G, Napieralski R, Vetter M, Thomssen C, Perkins J, Lauber J, Ulm K, Martens JWM, Weichert W, Kiechle M. PITX2 DNA-Methylierung: Erster klinisch validierter prädiktiver Marker zur Vorhersage des Ansprechens auf anthrazyklin-basierte Chemotherapie bei Brustkrebspatientinnen mit hohem Rezidivrisiko. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1655534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Paepke
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - OG Wilhelm
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - M Schmitt
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - A Noske
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - G Schricker
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - R Napieralski
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - M Vetter
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - C Thomssen
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - J Perkins
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - J Lauber
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - K Ulm
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - JWM Martens
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - W Weichert
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| | - M Kiechle
- Klinik und Poliklinik für Frauenheilkunde/Institut für Pathologie, Klinikum rechts der Isar, Technische Universität München, Comprehensive Cancer Center; Qiagen GmbH, Hilden und Therawis Diagnostics GmbH München, Deutschland
| |
Collapse
|
11
|
Tripathy D, Bardia A, Blum JL, Rocque G, Wilks S, Lakhanpal S, Migas J, Cappelleri J, Perkins J, Comstock G, Wang Y. Abstract OT3-05-03: POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-ot3-05-03] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: P is a novel cyclin-dependent kinase 4/6 inhibitor approved in the United States and Canada in combination with endocrine therapy for HR+/human epidermal growth factor receptor 2–negative (HER2-) advanced breast cancer (ABC). Despite promising trial results, not all patients respond to P. Moreover, despite a median age at diagnosis of 62 years, elderly patients are underrepresented in targeted therapy trials, including the PALOMA studies assessing P. It is important to understand P use in real-world practice settings, including tolerability and outcomes in the vulnerable older population. In addition, understanding the mechanisms of P response or resistance is critical to identify clinical factors and biomarkers that can predict which patients will benefit from P. This multicenter observational and biomarker study will seek to address these and other data gaps.
Trial Design: This is a prospective, noninterventional study of 1500 patients treated with P from 100 US and 10 Canadian sites. Study duration will span 2 years of recruitment and 3 years of follow-up after P treatment, until patient withdrawal from the study or death. Study participation is not intended to alter routine treatment; all treatment decisions, including type and timing of disease monitoring, are at the discretion of the treating physician and patient.
Eligibility: Eligible patients are aged ≥18 years with a diagnosis of adenocarcinoma of the breast with (1) evidence of advanced or metastatic disease not amenable to treatment with curative intent, (2) documented HR+/HER2- status, and (3) planned treatment with P. Patients with a life expectancy <3 months at initial diagnosis, those participating in interventional trials, and those receiving active treatment for malignancies other than ABC at enrollment are ineligible.
Aims: In a large real-world cohort of HR+/HER2- ABC patients treated with P in routine clinical practice, this study aims to assess the following: prescribing and treatment patterns for ABC before, during, and after P therapy; overall clinical response to P; biomarker assessment investigating potential mechanisms of response and resistance to P based on genomic analyses of blood samples; patient quality of life, as measured by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30; geriatric assessments in patients aged ≥70 years at enrollment based on the G8 Geriatric Screening Tool and the Activities of Daily Living questionnaire; and sequencing of treatment for metastatic disease. Other outcomes to be assessed include survival and toxicity.
Methods: Data will be collected from routine clinical assessments. Patients will have the option to provide blood samples drawn at standard-of-care intervals at baseline, during P treatment, and at the end of treatment for potential biomarker identification. Analyses will be primarily descriptive, with point estimates and confidence intervals as well as Kaplan-Meier methods used to assess time-to-event outcomes.
Accrual: Presently, 46 patients from 20 sites are enrolled.
Funding: Pfizer Inc.
Citation Format: Tripathy D, Bardia A, Blum JL, Rocque G, Wilks S, Lakhanpal S, Migas J, Cappelleri J, Perkins J, Comstock G, Wang Y. POLARIS: Palbociclib (P) in hormone receptor-positive (HR+) advanced breast cancer: A prospective multicenter noninterventional study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr OT3-05-03.
Collapse
Affiliation(s)
- D Tripathy
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - A Bardia
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - JL Blum
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - G Rocque
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - S Wilks
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - S Lakhanpal
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - J Migas
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - J Cappelleri
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - J Perkins
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - G Comstock
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| | - Y Wang
- Univeristy of Texas, MD Anderson Cancer Center, Houston, TX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA; Texas Oncology, Baylor-Sammons Cancer Center, US Oncology, Dallas, TX; University of Alabama Birmingham, Birmingham, AL; Texas Oncology, San Antonio, TX; St. Vincent's Birmingham, Birmingham, AL; OSF St Joseph Medical Center, Bloomington, IL; Pfizer Inc, Groton, CT; Pfizer Inc, New York, NY; Pfizer Inc, Santa Rosa, CA
| |
Collapse
|
12
|
Najmabadi F, Raffray AR, Abdel-Khalik SI, Bromberg L, El-Guebaly LA, Goodin D, Haynes D, Latkowski J, Meier W, Moore R, Neff S, Olson CL, Perkins J, Petti D, Petzoldt R, Rose DV, Sharp WM, Sharpe P, Tillack MS, Waganer L, Welch D, Yoda M, Yu SS, Zaghloul M. Operational Windows for Dry-Wall and Wetted-Wall IFE Chambers. Fusion Science and Technology 2017. [DOI: 10.13182/fst04-a580] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- F. Najmabadi
- University of California, San Diego, Department of Electrical and Computer Engineering and Center for Energy Research, La Jolla, California 92093
| | - A. R. Raffray
- University of California, San Diego, Mechanical and Aerospace Engineering Department and Center for Energy Research, La Jolla, California 92093
| | - S. I. Abdel-Khalik
- Georgia Institute of Technology, Woodruff School of Mechanical Engineering, Atlanta, Georgia 30332-0405
| | - L. Bromberg
- Georgia Institute of Technology, Woodruff School of Mechanical Engineering, Atlanta, Georgia 30332-0405
| | - L. A. El-Guebaly
- Georgia Institute of Technology, Woodruff School of Mechanical Engineering, Atlanta, Georgia 30332-0405
| | - D. Goodin
- General Atomics, San Diego, California 92186
| | - D. Haynes
- Georgia Institute of Technology, Woodruff School of Mechanical Engineering, Atlanta, Georgia 30332-0405
| | - J. Latkowski
- Lawrence Livermore National Laboratory, Livermore, California 94550
| | - W. Meier
- Lawrence Livermore National Laboratory, Livermore, California 94550
| | - R. Moore
- Idaho National Engineering and Environmental Laboratory, Fusion Safety Program, EROB E-3 MS 3815, Idaho Falls, Idaho 83415-3815
| | - S. Neff
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - C. L. Olson
- Sandia National Laboratories, Albuquerque, New Mexico 87185
| | - J. Perkins
- Lawrence Livermore National Laboratory, Livermore, California 94550
| | - D. Petti
- Idaho National Engineering and Environmental Laboratory, Fusion Safety Program, EROB E-3 MS 3815, Idaho Falls, Idaho 83415-3815
| | - R. Petzoldt
- General Atomics, San Diego, California 92186
| | - D. V. Rose
- Mission Research Corporation, Albuquerque, New Mexico 87110
| | - W. M. Sharp
- Lawrence Livermore National Laboratory, Livermore, California 94550
| | - P. Sharpe
- Idaho National Engineering and Environmental Laboratory, Fusion Safety Program, EROB E-3 MS 3815, Idaho Falls, Idaho 83415-3815
| | - M. S. Tillack
- University of California, San Diego, Mechanical and Aerospace Engineering Department and Center for Energy Research, La Jolla, California 92093
| | - L. Waganer
- Boeing High Energy Systems, St. Louis, Missouri 63166
| | - D.R. Welch
- Mission Research Corporation, Albuquerque, New Mexico 87110
| | - M. Yoda
- Georgia Institute of Technology, Woodruff School of Mechanical Engineering, Atlanta, Georgia 30332-0405
| | - S. S. Yu
- Lawrence Berkeley National Laboratory, Berkeley, California 94720
| | - M. Zaghloul
- University of California, San Diego, Mechanical and Aerospace Engineering Department and Center for Energy Research, La Jolla, California 92093
| | | |
Collapse
|
13
|
Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 52:438-444. [PMID: 27819684 DOI: 10.1038/bmt.2016.269] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2016] [Revised: 08/23/2016] [Accepted: 08/24/2016] [Indexed: 12/28/2022]
Abstract
HLA-matched related or unrelated donors are not universally available. Consequently, patients can be offered hematopoietic stem cell transplantation (HSCT) from alternative donors, including mismatched unrelated donors (MMURD), known to cause a higher incidence of acute GVHD (aGVHD) and chronic GVHD. In vivo T-cell-depletion strategies, such as antithymocyte globulin (ATG) therapy, significantly decrease the risk of GVHD. We performed a multicenter, retrospective study comparing tacrolimus (TAC) and sirolimus (SIR) with or without ATG in 104 patients (TAC-SIR=45, TAC-SIR-ATG=59) who underwent MMURD HSCT. Use of ATG was associated with a lower incidence, albeit not statistically significant, of grades 2-4 aGVHD (46% vs 64%, P=0.09), no difference in grades 3-4 aGVHD (10% vs 15%, P=0.43), a trend for a lower incidence of moderate/severe chronic GVHD (16% vs 37%, P=0.09) and more frequent Epstein-Barr virus reactivation (54% vs 18%, P=0.0002). There were no statistically significant differences in 3-year overall survival (OS) (TAC-SIR-ATG=40% (95% confidence interval (CI)=24-56%) vs TAC-SIR=54% (95% CI=37-70%), P=0.43) or 3-year cumulative incidence of relapse/progression (TAC-SIR-ATG=40% (95% CI=28-58%) vs TAC-SIR=22% (95% CI=13-39%), P=0.92). An intermediate Center for International Blood & Marrow Transplant Research disease risk resulted in a significantly lower non-relapse mortality and better OS at 3 years. Our study suggests that addition of ATG to TAC-SIR in MMURD HSCT does not affect OS when compared with TAC-SIR alone.
Collapse
Affiliation(s)
- M A Kharfan-Dabaja
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - R Parody
- Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Sevilla, Spain
| | - J Perkins
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.,College of Pharmacy, University of South Florida, Tampa, FL, USA
| | | | | | - L Vazquez
- Hospital Universitario de Salamanca, Salamanca, Spain
| | - D Caballero
- Hospital Universitario de Salamanca, Salamanca, Spain
| | - J Falantes
- Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Sevilla, Spain
| | - J Shapiro
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - G Ortí
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - P Barba
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - D Valcárcel
- Hospital Universitario Vall d'Hebron, Barcelona, Spain
| | - A Esquirol
- Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | - R Martino
- Hospital Santa Creu i Sant Pau, Barcelona, Spain
| | - J L Piñana
- Hospital Clínico de Valenci, Valencia, Spain
| | - C Solano
- Hospital Clínico de Valenci, Valencia, Spain
| | - A Tsalatsanis
- Center for Evidence-Based Medicine, University of South Florida College of Medicine, Tampa, FL, USA
| | - J Pidala
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - C Anasetti
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J A Perez-Simón
- Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC, Sevilla, Spain
| |
Collapse
|
14
|
Weigle H, Trigonis R, Bunn D, Krakauer D, Long L, Perkins J. 345 Severe Sepsis: What Gets it Right? A Comparison of the Quick Sequential Organ Failure Assessment Versus Systemic Inflammatory Response Syndrome Criteria. Ann Emerg Med 2016. [DOI: 10.1016/j.annemergmed.2016.08.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
15
|
Perkins J, Voore N, Sanna S, Patel J, Mann E, Gozu A. 363 Assessment of an Emergency Department Chest Pain Patient Cohort at Low Risk for Significant Adverse Events During Admission for Acute Coronary Syndrome. Ann Emerg Med 2015. [DOI: 10.1016/j.annemergmed.2015.07.399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
16
|
Halldorson JB, Rayhill S, Bakthavatsalam R, Montenovo M, Dick A, Perkins J, Reyes J. Serum alkaline phosphatase and bilirubin are early surrogate markers for ischemic cholangiopathy and graft failure in liver transplantation from donation after circulatory death. Transplant Proc 2015; 47:465-8. [PMID: 25769592 DOI: 10.1016/j.transproceed.2014.10.055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2014] [Revised: 10/15/2014] [Accepted: 10/28/2014] [Indexed: 01/08/2023]
Abstract
Liver transplantation with the use of donation after circulatory death (DCD) is associated with ischemic cholangiopathy (IC) often leading to graft loss. We hypothesized that serial postoperative analysis of alkaline phosphatase and bilirubin might identify patients who would later on develop ischemic cholangiopathy and/or graft loss, allowing early recognition and potentially retransplantation. The University of Washington DCD experience totals 89 DCD liver transplantations performed from 2003 to 2011 with Kaplan-Meier estimated 5-year patient and graft survival rates of 81.6% and 75.6%, respectively; 84/89 patients transplanted with DCD livers lived ≥ 60 days after transplantation and were analyzed. Serum bilirubin and alkaline phosphatase levels at 1 week, 2 week, 1 month, and 2 months after transplantation were analyzed. Two-month serum bilirubin and alkaline phosphatase proved to have the strongest associations with development of IC and graft failure. Two-month alkaline phosphatase of <100 U/L had a negative predictive value of 97% for development of IC. Two-month alkaline phosphatase demonstrated an inflection starting at >300 U/L strongly associated with development of IC (P < .0001). Serum bilirubin at 2 months was most strongly associated with graft failure within the 1st year with a strong inflection point at 2.5 mg/dL (P = .0001). All jaundiced recipients at 60 days after transplantation (bilirubin >2.5 mg/dL) developed graft failure within the 1st year (P < .0001). Use of these early surrogate markers could facilitate prioritization and early retransplantation for DCD liver recipients with allografts destined for failure.
Collapse
Affiliation(s)
- J B Halldorson
- Division of Transplantation, University of California, San Diego, California.
| | - S Rayhill
- Division of Transplantation, University of Washington, Seattle, Washington
| | - R Bakthavatsalam
- Division of Transplantation, University of Washington, Seattle, Washington
| | - M Montenovo
- Division of Transplantation, University of Washington, Seattle, Washington
| | - A Dick
- Division of Transplantation, University of Washington, Seattle, Washington
| | - J Perkins
- Division of Transplantation, University of Washington, Seattle, Washington
| | - J Reyes
- Division of Transplantation, University of Washington, Seattle, Washington
| |
Collapse
|
17
|
Blanca-Lopez N, Perez-Alzate D, Ruano F, Garcimartin M, de la Torre V, Mayorga C, Somoza ML, Perkins J, Blanca M, Canto MG, Torres MJ. Selective immediate responders to amoxicillin and clavulanic acid tolerate penicillin derivative administration after confirming the diagnosis. Allergy 2015; 70:1013-9. [PMID: 25913298 DOI: 10.1111/all.12636] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2015] [Indexed: 11/27/2022]
Abstract
BACKGROUND An increasing number of patients show immediate selective hypersensitivity reactions to clavulanic acid (CLV) and amoxicillin (AX), probably due to their increased prescription. The maintenance of this response should be established. OBJECTIVE To assess that the immediate hypersensitivity selective response to AX or to CLV is maintained after repeated administration of penicillin G (PG)/penicillin V (PV) and AX. METHODS Patients with proven immediate hypersensitivity to AX (Group A) or CLV (Group B) were included. Diagnosis was performed using skin tests with major and minor determinants of PG (PPL/MDM), AX and CLV and by drug provocation test (DPT) if required. Selectivity was established by confirming tolerance to PG/PV (Group A) and to PG/PV and AX (Group B). The maintenance of the selective response was verified by repeating DPT, 15 days after the initial investigation, with the same procedure. RESULTS Of 51 patients, 78% belonged to Group A and 22% to Group B. Most had anaphylaxis. In Group A, 72% were skin test positive; 28% required DPT. In Group B, 63% were skin test positive; 37% required DPT. Only two AX-selective cases developed positive responses after re-provocation with PG/PV. No cases selective for CLV developed a positive response to PG, PV or AX. DISCUSSION The selective response to AX appears consistent, and a response to penicillin determinants only develops in a minority of cases. For the case of CLV, the selective response appears not to be modified by exposure to penicillin determinants, meaning that patients with CLV allergy can take penicillin derivatives safely.
Collapse
Affiliation(s)
| | | | - F. Ruano
- Allergy Service; Hospital Infanta Leonor; Madrid Spain
| | | | | | - C. Mayorga
- Allergy Service; Hospital Infanta Leonor; Madrid Spain
| | - M. L. Somoza
- Allergy Service; Hospital Infanta Leonor; Madrid Spain
| | - J. Perkins
- Allergy Service; Hospital Infanta Leonor; Madrid Spain
| | - M. Blanca
- Allergy Unit; IBIMA; Regional University Hospital of Malaga; Málaga Spain
| | - M. G. Canto
- Allergy Service; Hospital Infanta Leonor; Madrid Spain
| | - M. J. Torres
- Allergy Unit; IBIMA; Regional University Hospital of Malaga; Málaga Spain
| |
Collapse
|
18
|
Chai J, Biasiolli L, Li L, Handa A, Perkins J, Hands L, Sideso E, Jezzard P, Robson M, Choudhury R. In-vivo carotid plaque characterisation using quantitative T2 map: Histological validation and lipid quantification. Atherosclerosis 2015. [DOI: 10.1016/j.atherosclerosis.2015.04.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
19
|
Verraich J, Shivaram G, Ghodke B, Vaidya S, Zopf D, Perkins J. Pre-operative n-butyl-2-cyanoacrylate glue embolization of pediatric head and neck venous malformations: technique and clinical outcomes. J Vasc Interv Radiol 2015. [DOI: 10.1016/j.jvir.2014.12.120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
20
|
Halldorson JB, Bakthavatsalam R, Montenovo M, Dick A, Rayhill S, Perkins J, Reyes J. Differential rates of ischemic cholangiopathy and graft survival associated with induction therapy in DCD liver transplantation. Am J Transplant 2015; 15:251-8. [PMID: 25534449 DOI: 10.1111/ajt.12962] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Revised: 07/09/2014] [Accepted: 08/04/2014] [Indexed: 01/25/2023]
Abstract
Transplantation utilizing donation after circulatory death (DCD) donors is associated with ischemic cholangiopathy (IC) and graft loss. The University of Washington (UW) DCD experience totals 89 DCD liver transplants performed between 2003 and 2011. Overall outcome after DCD liver transplantation at UW demonstrates Kaplan-Meier estimated 5-year patient and graft survival rates of 81.6% and 75.6%, respectively, with the great majority of patient and graft losses occurring in the first-year posttransplant from IC. Our program has almost exclusively utilized either anti-thymocyte globulin (ATG) or basiliximab induction (86/89) for DCD liver transplantations. Analysis of the differential effect of induction agent on graft survival demonstrated graft survival of 96.9% at 1 year for ATG versus 75.9% for basiliximab (p = 0.013). The improved survival did not appear to be from a lower rate of rejection (21.9% vs. 22.2%) but rather a differential rate of IC, 35.2% for basiliximab versus 12.5% for ATG (p = 0.011). Multivariable analysis demonstrated induction agent to be independently associated with graft survival and IC free graft survival when analyzed against variables including donor age, fWIT, donor cold ischemia time and transplant era.
Collapse
Affiliation(s)
- J B Halldorson
- Division of Transplantation, University of California, San Diego, CA
| | | | | | | | | | | | | |
Collapse
|
21
|
Chai J, Biasiolli L, Li L, Handa A, Perkins J, Hands L, Sideso E, Jezzard P, Robson M, Choudhury R. In-vivo carotid plaques characterisation using quantitative T2 map: histological validation and lipid quantification. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.10.047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
22
|
Kairis O, Kosmas C, Karavitis C, Ritsema C, Salvati L, Acikalin S, Alcalá M, Alfama P, Atlhopheng J, Barrera J, Belgacem A, Solé-Benet A, Brito J, Chaker M, Chanda R, Coelho C, Darkoh M, Diamantis I, Ermolaeva O, Fassouli V, Fei W, Feng J, Fernandez F, Ferreira A, Gokceoglu C, Gonzalez D, Gungor H, Hessel R, Juying J, Khatteli H, Khitrov N, Kounalaki A, Laouina A, Lollino P, Lopes M, Magole L, Medina L, Mendoza M, Morais P, Mulale K, Ocakoglu F, Ouessar M, Ovalle C, Perez C, Perkins J, Pliakas F, Polemio M, Pozo A, Prat C, Qinke Y, Ramos A, Ramos J, Riquelme J, Romanenkov V, Rui L, Santaloia F, Sebego R, Sghaier M, Silva N, Sizemskaya M, Soares J, Sonmez H, Taamallah H, Tezcan L, Torri D, Ungaro F, Valente S, de Vente J, Zagal E, Zeiliguer A, Zhonging W, Ziogas A. Evaluation and selection of indicators for land degradation and desertification monitoring: types of degradation, causes, and implications for management. Environ Manage 2014; 54:971-82. [PMID: 23811772 DOI: 10.1007/s00267-013-0110-0] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2012] [Accepted: 06/07/2013] [Indexed: 05/25/2023]
Abstract
Indicator-based approaches are often used to monitor land degradation and desertification from the global to the very local scale. However, there is still little agreement on which indicators may best reflect both status and trends of these phenomena. In this study, various processes of land degradation and desertification have been analyzed in 17 study sites around the world using a wide set of biophysical and socioeconomic indicators. The database described earlier in this issue by Kosmas and others (Environ Manage, 2013) for defining desertification risk was further analyzed to define the most important indicators related to the following degradation processes: water erosion in various land uses, tillage erosion, soil salinization, water stress, forest fires, and overgrazing. A correlation analysis was applied to the selected indicators in order to identify the most important variables contributing to each land degradation process. The analysis indicates that the most important indicators are: (i) rain seasonality affecting water erosion, water stress, and forest fires, (ii) slope gradient affecting water erosion, tillage erosion and water stress, and (iii) water scarcity soil salinization, water stress, and forest fires. Implementation of existing regulations or policies concerned with resources development and environmental sustainability was identified as the most important indicator of land protection.
Collapse
Affiliation(s)
- Or Kairis
- Laboratory of Soils, Agricultural University of Athens, Iera Odos 75, Athens, 11855, Greece
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Kosmas C, Kairis O, Karavitis C, Ritsema C, Salvati L, Acikalin S, Alcala M, Alfama P, Atlhopheng J, Barrera J, Belgacem A, Solé-Benet A, Brito J, Chaker M, Chanda R, Coelho C, Darkoh M, Diamantis I, Ermolaeva O, Fassouli V, Fei W, Feng J, Fernandez F, Ferreira A, Gokceoglu C, Gonzalez D, Gungor H, Hessel R, Juying J, Khatteli H, Khitrov N, Kounalaki A, Laouina A, Lollino P, Lopes M, Magole L, Medina L, Mendoza M, Morais P, Mulale K, Ocakoglu F, Ouessar M, Ovalle C, Perez C, Perkins J, Pliakas F, Polemio M, Pozo A, Prat C, Qinke Y, Ramos A, Ramos J, Riquelme J, Romanenkov V, Rui L, Santaloia F, Sebego R, Sghaier M, Silva N, Sizemskaya M, Soares J, Sonmez H, Taamallah H, Tezcan L, Torri D, Ungaro F, Valente S, de Vente J, Zagal E, Zeiliguer A, Zhonging W, Ziogas A. Evaluation and selection of indicators for land degradation and desertification monitoring: methodological approach. Environ Manage 2014; 54:951-970. [PMID: 23797485 DOI: 10.1007/s00267-013-0109-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/09/2012] [Accepted: 06/07/2013] [Indexed: 06/02/2023]
Abstract
An approach to derive relationships for defining land degradation and desertification risk and developing appropriate tools for assessing the effectiveness of the various land management practices using indicators is presented in the present paper. In order to investigate which indicators are most effective in assessing the level of desertification risk, a total of 70 candidate indicators was selected providing information for the biophysical environment, socio-economic conditions, and land management characteristics. The indicators were defined in 1,672 field sites located in 17 study areas in the Mediterranean region, Eastern Europe, Latin America, Africa, and Asia. Based on an existing geo-referenced database, classes were designated for each indicator and a sensitivity score to desertification was assigned to each class based on existing research. The obtained data were analyzed for the various processes of land degradation at farm level. The derived methodology was assessed using independent indicators, such as the measured soil erosion rate, and the organic matter content of the soil. Based on regression analyses, the collected indicator set can be reduced to a number of effective indicators ranging from 8 to 17 in the various processes of land degradation. Among the most important indicators identified as affecting land degradation and desertification risk were rain seasonality, slope gradient, plant cover, rate of land abandonment, land-use intensity, and the level of policy implementation.
Collapse
|
24
|
Lee J, Sung J, Lee J, Perkins J. Biomarker difference between controlled and uncontrolled hypertension among us adults: National health and nutrition examination survey 2005-2008. Atherosclerosis 2014. [DOI: 10.1016/j.atherosclerosis.2014.05.152] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
25
|
Ustinova KI, Perkins J, Leonard WA, Hausbeck CJ. Virtual reality game-based therapy for treatment of postural and co-ordination abnormalities secondary to TBI: a pilot study. Brain Inj 2014; 28:486-95. [PMID: 24702281 DOI: 10.3109/02699052.2014.888593] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
PRIMARY OBJECTIVE The study objective was to test the efficacy of game-based virtual reality (VR) therapy as a mean of correcting postural and co-ordination abnormalities in individuals with traumatic brain injury (TBI). Therapy was done with interactive customized VR games and scenarios, utilizing an Xbox Kinect sensor. RESEARCH DESIGN The study was a pilot project using the structure of a phase II clinical trial. METHODS AND PROCEDURES Fifteen participants with mild-to-moderate chronic TBI-related balance and motor co-ordination impairments participated in 15 sessions, each lasting ∼50-55 minutes, scheduled 2-3 times a week over 5-6 consecutive weeks. Participants were evaluated at baseline, immediately after the final session and in a 1-month follow-up with a battery of clinical tests (measuring postural stability, gait and co-ordination) and movement performance parameters. Movement parameters included arm-leg co-ordination, dynamic stability and arm precision, calculated from kinematic data recorded with Xbox Kinect sensor. RESULTS Following therapy, most participants improved their static and dynamic postural stability, gait and arm movements. These effects persisted over the retention interval. CONCLUSIONS Results will be used to improve the VR program, with the goal of producing a cost-effective, accessible and easy to individualize therapeutic approach. The pilot data will be used for designing a larger scale clinical trial.
Collapse
Affiliation(s)
- K I Ustinova
- The Herbert H. and Grace A. Dow College of Health Professions, Central Michigan University , MI , USA and
| | | | | | | |
Collapse
|
26
|
Parmar SR, Bookout R, Shapiro JF, Tombleson R, Perkins J, Kim J, Yue B, Tomblyn M, Alsina M, Nishihori T. Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. Bone Marrow Transplant 2014; 49:761-6. [PMID: 24662419 DOI: 10.1038/bmt.2014.56] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2013] [Revised: 01/28/2014] [Accepted: 02/04/2014] [Indexed: 12/22/2022]
Abstract
High-dose melphalan at 200 mg/m(2) can be administered in 1 day or over 2 consecutive days before autologous hematopoietic cell transplantation (HCT) for multiple myeloma (MM). Limited data exist on the comparison of the two dosing schedules. A retrospective study of 278 consecutive MM patients receiving high-dose melphalan from January 2010 to December 2012 was conducted. Objectives were to compare the length of hospitalization, toxicity profile, response rates, PFS and OS. One hundred and eighty five patients received 2-day dosing and 93 received 1-day dosing. The two end points of the 95% confidence interval (CI) for the difference did not exceed the preselected margin, therefore the length of hospitalization was considered equivalent. No significant differences were found for response rates, PFS and OS. The toxicity profile was similar with the exception of more frequent ⩾grade 3 oral mucositis in the 2-day group (13.5% vs 5.4%; odds ratio 3.07 (95% CI:1.11-8.48); P=0.03). High-dose melphalan, given either in 1 day or over 2 days, produced comparable treatment outcomes except for increased grade 3/4 mucositis in the 2-day regimen. One-day dosing could shorten the hospital stay by 1 day and may allow better resource utilization.
Collapse
Affiliation(s)
- S R Parmar
- Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - R Bookout
- Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J F Shapiro
- Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - R Tombleson
- Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - J Perkins
- University of South Florida College of Pharmacy, Tampa, FL, USA
| | - J Kim
- Biostatistics Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - B Yue
- Biostatistics Core, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - M Tomblyn
- Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - M Alsina
- Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| | - T Nishihori
- Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
| |
Collapse
|
27
|
Ustinova K, Perkins J. Virtual reality game-based therapy for restoring postural and coordination abnormalities in patients with TBI. J Neurol Sci 2013. [DOI: 10.1016/j.jns.2013.07.1981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
28
|
Field T, Perkins J, Nishori T, Pidala J, Fernandez H, Tomblyn M, Kharfan-Dabaja M, Perez L, Komrokji R, Lancet J, Kim J, Ayala E, Alsina M, Ochoa-Bayona JL, Locke F, Betts B, List A, Anasetti C. Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
29
|
Pidala J, Kim J, Schell M, Hillgruber R, Nye V, Ayala E, Alsina M, Betts B, Bookout R, Fernandez H, Field T, Locke F, Nishihori T, Ochoa J, Perez L, Perkins J, Shapiro J, Tate C, Tomblyn M, Anasetti C. Effectiveness of Unrelated Donor Allogeneic Hematopoietic Cell Transplantation: Results of a Donor Vs. No Donor Analysis. Biol Blood Marrow Transplant 2012. [DOI: 10.1016/j.bbmt.2011.12.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Davis M, Goldstein D, George S, Casali R, Li S, Perkins J, Demetri G. 1140 POSTER Asthenia and Fatigue as Predictors of Sunitinib Efficacy in Gastrointestinal Stromal Tumour (GIST). Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70783-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
31
|
Davis M, Figlin R, Hutson T, Goldstein D, Li S, Perkins J, Motzer R. 1139 POSTER Asthenia and Fatigue as Potential Biomarkers of Sunitinib Efficacy in Metastatic Renal Cell Carcinoma. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)70782-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
32
|
Ustinova K, Perkins J. Gaze and viewing angle influence visual stabilization of upright posture. Brain Behav 2011; 1:19-25. [PMID: 22398978 PMCID: PMC3217671 DOI: 10.1002/brb3.10] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/31/2011] [Revised: 05/19/2011] [Accepted: 05/27/2011] [Indexed: 11/13/2022] Open
Abstract
Focusing gaze on a target helps stabilize upright posture. We investigated how this visual stabilization can be affected by observing a target presented under different gaze and viewing angles. In a series of 10-second trials, participants (N = 20, 29.3 ± 9 years of age) stood on a force plate and fixed their gaze on a figure presented on a screen at a distance of 1 m. The figure changed position (gaze angle: eye level (0°), 25° up or down), vertical body orientation (viewing angle: at eye level but rotated 25° as if leaning toward or away from the participant), or both (gaze and viewing angle: 25° up or down with the rotation equivalent of a natural visual perspective). Amplitude of participants' sagittal displacement, surface area, and angular position of the center of gravity (COG) were compared. Results showed decreased COG velocity and amplitude for up and down gaze angles. Changes in viewing angles resulted in altered body alignment and increased amplitude of COG displacement. No significant changes in postural stability were observed when both gaze and viewing angles were altered. Results suggest that both the gaze angle and viewing perspective may be essential variables of the visuomotor system modulating postural responses.
Collapse
Affiliation(s)
- Ki Ustinova
- Graduate Program in Physical Therapy, Herbert H. and Grace A. Dow College of Health Professions, Central Michigan University Michigan 48859
| | | |
Collapse
|
33
|
Komrokji R, Alrawi E, Al Ali N, Perkins J, Field T, Epling-Burnette P, Zhang L, Lancet J, List A. 276 Outcome of azacitidine treatment of patients with therapy related myelodysplastic syndrome. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70278-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
34
|
Rayhill S, Schwartz J, Ham J, Carithers R, Lei Y, Bhattacharya R, Liou I, Landis C, Lamaye A, Rakita R, Dick A, Healey P, Halldorson J, Bhakthavatsalam R, Perkins J, Reyes J. The use of hepatitis B core antibody-positive donor livers does not appear to have a deleterious effect on graft survival in liver transplantation for hepatitis C. Transplant Proc 2011; 42:4141-4. [PMID: 21168646 DOI: 10.1016/j.transproceed.2010.09.023] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2010] [Accepted: 09/09/2010] [Indexed: 11/27/2022]
Abstract
INTRODUCTION The use of hepatitis B core antibody-positive donor livers (HBcAb(+)) has steadily increased. According to a recent multivariate analysis of United Network for Organ Sharing (UNOS) data, there was no significant increase in the risk of using these donors. The increased risk among the hepatitis C virus (HCV)-positive subgroup noted in a univariate model disappeared upon multivariate analysis. However, deeper scrutiny may show that HCV-positive recipients may be at increased risk with HBcAb(+) donor livers, as they require simultaneous treatment with two antiviral regimens there may be deleterious interactions between the two viruses. Thus, the issue of HBcAb(+) donors for HCV-positive recipients merits more detailed analysis. METHODS Using UNOS registry data of all liver transplantations performed during the Model for End-Stage Liver Disease era from February 2002 through November 2007, we analyzed graft survival using Kaplan-Meier and Cox regression analyses. RESULTS Of the 12,543 HCV-positive recipients, 2,543 received HBcAb(-) livers and 853 received HBcAb(+) livers. While Kaplan-Meier analysis showed significantly lower graft survival among HCV-negative recipients of HBcAb(+) livers (P = .0001), there was no significant effect on graft survival among the HCV-positive population (P = .2). To detect an early effect in HCV-positive recipients, we examined 1-year graft survival, observing no significant difference (P = .3). To exclude a possible late effect, we examined graft survival in the HCV-positive population conditional upon surviving at least 1 year after transplantation; no significant difference was observed (P = .6). The elimination of potentially confounding codiagnoses, such as hepatitis B virus, alcoholism, acute graft failure, and hepatocellular cancer did not alter the findings. On univariate analysis, the lack of a significant effect persisted among the HCV population. However, the significant effect observed in the univariate model for the HCV-negative population became insignificant when combined with other risk factors in the multivariate model. CONCLUSION The use of HBcAb(+) livers in recipients with HCV did not appear to have a significant impact on graft survival.
Collapse
Affiliation(s)
- S Rayhill
- Department of Surgery, University of Washington, Seattle, Washington 98195-6175, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Ginley D, Coutts T, Perkins J, Young D, Li X, Parilla P. Next-Generation Transparent Conducting Oxides for Photovoltaic Cells: an Overview. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-668-h2.7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTTransparent conducting oxides (TCOs) are becoming a more critical element in thin-film photovoltaic devices. In the continued drive to increase efficiency and stability while reducing cost and optimizing performance, the optical, electrical, and materials properties of TCOs gain increasing importance. TCOs can perform a variety of important functions, including contacts, antireflection coatings, and chemical barriers. In this paper, we will review some of the current advances in the field of transparent conductors and, where possible, will relate these advances to thin-film photovoltaic devices. Highlights will be on the rapidly growing collection of new n- and p-type materials; the implications of these materials on PV have not been fully assessed.
Collapse
|
36
|
Perkins J, Readey D, Alleman J, del Cueto J, Li X, Coutts T, Stauber R, Duncan C, Young D, Parilla P, Keyes B, Gedvilas L, Balzar D, Wang Q, Ginley D. A Combinatorial Approach to TCO Synthesis and Characterization. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-666-f1.6] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
ABSTRACTWe have developed the deposition, characterization and analysis tools necessary for a combinatorial approach to thin film metal oxides, with a special focus on transparent conducting oxides (TCOs). We are presently depositing compositionally graded libraries using mutli-target sputtering and CVD. The initial collection of characterization tools includes UV/VIS/NIR transmission/reflection, FTIR reflectance, Raman scattering, 4-point conductivity, thickness, xray diffraction and electron microprobe. In addition to allowing for a more complete empirical optimization of TCO properties, we expect to develop an improved basic understanding of TCOs, especially in the area of p-type TCOs. This paper provides an overview of our current combinatorial material science program as applied specifically to TCOs.
Collapse
|
37
|
Abstract
ABSTRACTThe character and mechanism of two-way shape memory (TWSM) “training” has been investigated in a Cu-Zn-Al alloy by means of detailed thermomechanical evaluation and TEM observations. The progressive effects of training on the TWSM behaviour, as well as an accompanying substructural evolution, have been established. The results indicate a relationship between the substructural effects of cyclic thermoelastic martensitic transformation and the ability to exhibit TWSM. Microscopic studies reveal that as the number of cycles of thermoelastic transformation under stress increases, specific physical features develop in the parent phase submicrostructure. These take the form of dislocation structures which evolve into “vestigial” martensite markinqs. These in turn assist in the nucleation and growth of a preferred martensite plate arrangement on cooling which is similar to that induced under stress during the training cycles.
Collapse
|
38
|
Field T, Perkins J, Nishihori T, Pidala J, Tomblyn M, Fernandez H, Perez L, Kharfan-Dabaja M, Komrokji R, Lancet J, Ayala E, Alsina M, Ochoa L, Kim J, List A, Anasetti C. Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: Comparison of Survival in Patients With an Available Donor Compared to Patients Without a Donor in Patients Up to Age 75. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
39
|
Wang Q, Perkins J, Moutinho H, To B, Branz HM. Amorphous to Microcrystalline Transition in Thickness-graded Hot-Wire CVD Silicon Films. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-715-a17.1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AbstractWe study the amorphous to microcrystalline silicon phase transition in hot-wire chemical vapor deposition thin-film silicon by depositing a series of unique, thickness-graded, samples on a glass substrate at 200°C. By inserting or withdrawing a motor-driven shutter during growth, we make samples that vary from 200 to about 2000 Å thick across each 5-cm along stripe. Each stripe is grown at a different dilution ratio of hydrogen to silane in the source gas. The phase composition at various locations was determined by Raman and ultraviolet-reflectivity measurements. Atomic force microscopy (AFM) images of topology reveal that the surface changes from a rather smooth a-Si phase to more granular microcrystalline-Si (rms roughness increases from 10 to 47 Å).
Collapse
|
40
|
Pidala J, Tomblyn M, Nishihori T, Perkins J, Field T, Ayala E, Alsina M, Ochoa L, Locke F, Perez L, Fernandez H, Anasetti C. Sirolimus Induces Complete Remission of Acute Graft-Versus-Host Disease Without Systemic Glucocorticoids. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
41
|
Perkins J, Fields T, Kim J, Fernandez H, Perez L, Ayala E, Kharfan-Dabaja M, Tomblyn M, Sullivan D, Anasetti C. Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) in Combination With Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.444] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
42
|
Curtis CJ, Rivkin T, Miedaner A, Alleman J, Perkins J, Smith L, Ginley DS. Direct-Write Printing of Silver Metallizations on Silicon Solar Cells. ACTA ACUST UNITED AC 2011. [DOI: 10.1557/proc-730-v3.8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
AbstractDirect-write technologies offer the potential for low-cost materials-efficient deposition of contact metallizations for photovoltaics. We report on the inkjet printing of metal organic decomposition (MOD) inks with and without nanoparticle additions. Near-bulk conductivity of printed and sprayed metal films has been achieved for Ag and Ag nanocomposites. Good adhesion and ohmic contacts with a measured contact resistance of 400μΩ•cm2 have been observed between the sprayed silver films and a heavily doped n-type layer of Si. Silver deposited using the MOD ink burns through the Si3N4 antireflection coating when annealed at 850°C to form an ohmic contact to the n-Si underneath. An active solar cell device was fabricated using a top contact that was spray printed using the Ag MOD ink. Inkjet printed films show adhesion differences as a function of the process temperature and solvent. Silver lines with good adhesion and conductivity have been printed on glass with 100 μm resolution.
Collapse
|
43
|
Pidala J, Tomblyn M, Nishihori T, Perkins J, Field T, Ayala E, Bookout R, Conwell M, Perez L, Ochoa L, Alsina M, Shapiro J, Tate C, Locke F, Fernandez H, Anasetti C. ATG for the Prevention of Severe Acute Graft-Versus-Host Disease in Mismatched Unrelated Donor Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
44
|
Field T, Perkins J, Pidala J, Nishihori T, Tomblyn M, Fernandez H, Perez L, Karfan-Dabaja M, Komrokji R, Lancet J, Ayala E, Alsina M, Ochoa L, Kim J, List A, Anasetti C. Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML. Biol Blood Marrow Transplant 2011. [DOI: 10.1016/j.bbmt.2010.12.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Perkins J, Field T, Kim J, Kharfan-Dabaja MA, Ayala E, Perez L, Fernandez H, Fancher K, Tate C, Shaw LM, Milone MC, Gardiner JA, Miller S, Anasetti C. Pharmacokinetic targeting of i.v. BU with fludarabine as conditioning before hematopoietic cell transplant: the effect of first-dose area under the concentration time curve on transplant-related outcomes. Bone Marrow Transplant 2010; 46:1418-25. [PMID: 21132026 DOI: 10.1038/bmt.2010.315] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
We used pharmacokinetic (PK) targeting of BU in 145 consecutive patients treated with fludarabine and i.v. BU. BU was given once daily at 130 mg/m(2) per day on days 1 and 2; doses for days 3 and 4 were adjusted in 92 patients (63%) to an average daily area under the concentration-time curve (AUC) of 5300 μM/min. In the remaining 53 patients, the first-dose AUC was within the target range and no dosing adjustments were required. First-dose AUC, maximum concentration and clearance were not correlated with age, race, ethnicity, performance status, or hematopoietic cell transplant comorbidity index. Women had higher clearance than men (median 2.9 vs 2.5 mL/min/kg; P=0.001). BU toxicities were not associated with first-dose AUC or any other PK parameter measured. First-dose BU AUC was not associated with non-relapse mortality (NRM) or survival, but higher AUC was predictive of relapse. We did not find an increased risk of toxicity or NRM in patients with high first-dose AUC presumably because of the dose adjustment. We conclude that PK targeting of BU as described here provides a simple, safe and effective method of delivering high BU doses before transplantation in a wide variety of patients.
Collapse
Affiliation(s)
- J Perkins
- Blood and Marrow Transplant Program, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Verwaal R, Jansen M, Wu L, Segueilha L, Perkins J. Breakthrough technology for fermentative succinic acid production. J Biotechnol 2010. [DOI: 10.1016/j.jbiotec.2010.08.209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
47
|
Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, Ayala E, Perez L, Fernandez H. Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant 2010; 46:641-9. [PMID: 20711242 DOI: 10.1038/bmt.2010.190] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Myeloablative doses of BU and fludarabine followed by allogeneic hematopoietic cell transplantation offer effective therapy for AML. We anticipated that pharmacokinetic targeting of i.v. BU to 5300 μM/L min/day × 4 (targeted i.v. BU and fludarabine (t-i.v. BU/Flu)) would limit nonrelapse mortality (NRM) in adults up to 70 years of age. We assessed the safety and efficacy of t-i.v. BU/Flu in a series of 100 adults (median age 48, range 22-69 years) with AML in the first CR (CR1) with high risk of treatment failure (n=49), second CR (CR2, n=25), relapsed disease (REL, n=9), primary induction failure (PIF, n=16) and untreated (n=1). NRM was 3% at 100 days and 15% at 1 year. The cumulative incidence of relapse was 30.6% for CR1, 41.7% for CR2, 55.6% for REL and 58.6% for PIF. OS for primary AML in CR1 was 66% (95% confidence interval (CI): 46-80%) at 1 year, and 62% (95% CI: 42-77%) at 2 years. On multivariable modeling, remission status, moderate/severe chronic GVHD and day-90 BM chimerism ≥90% predicted improved OS. Importantly, there was no effect of age. t-i.v. BU/Flu provides effective disease control with encouraging NRM in patients up to age of 70 years.
Collapse
Affiliation(s)
- J Pidala
- Department of Blood and Marrow Transplantation, Moffitt Cancer Center, University of South Florida, Tampa, FL 33612, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Morris RJH, Fearn S, Perkins J, Kilner J, Dowsett MG, Beigalski MD, Rouleau CM. The use of low-energy SIMS (LE-SIMS) for nanoscale fuel cell material development. SURF INTERFACE ANAL 2010. [DOI: 10.1002/sia.3526] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
49
|
Gergis U, Markey K, Greene J, Kharfan-Dabaja M, Field T, Wetzstein G, Schell MJ, Huang Y, Anasetti C, Perkins J. Voriconazole provides effective prophylaxis for invasive fungal infection in patients receiving glucocorticoid therapy for GVHD. Bone Marrow Transplant 2010; 45:662-7. [PMID: 19684623 PMCID: PMC2850960 DOI: 10.1038/bmt.2009.210] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2009] [Revised: 05/25/2009] [Accepted: 06/19/2009] [Indexed: 12/05/2022]
Abstract
Patients on systemic glucocorticoids for GVHD after hematopoietic cell transplant are susceptible to invasive fungal infections (IFI), which greatly contribute to morbidity and mortality. We evaluated the efficacy of prophylactic treatment options (voriconazole or fluconazole vs itraconazole) for IFI by performing a retrospective review of patients on glucocorticoids for GVHD who were administered voriconazole (n=97), fluconazole (n=36) or itraconazole (n=36). IFI developed in 7/72 (10%) patients on fluconazole/itraconazole vs 2/97 (2%) on voriconazole (P=0.03) within the first 100 days of glucocorticoids. Five (7%) patients developed Aspergillus IFI on fluconazole/itraconazole, compared with none on voriconazole (0%) (P=0.008); Aspergillus IFI resulted in death in all five patients. We found that IFI occurred in patients who received an initial dose of at least 2 mg/kg/day of prednisone or equivalent; when the analysis was restricted to these patients, the hazard ratio (0.39; 95% confidence interval: 0.08-1.86) was consistent with a protective effect of voriconazole compared with fluconazole/itraconazole, although this subset analysis did not reach significance. OS at 100 days after start of glucocorticoids was 77% in patients administered fluconazole/itraconazole and 85% in those administered voriconazole (P=0.22). Our results suggest that voriconazole is more effective than fluconazole/itraconazole in preventing IFI, especially aspergillosis, in patients receiving glucocorticoids post transplant.
Collapse
Affiliation(s)
- U Gergis
- Department of Medicine, Weill Cornell Medical College, New York, NY, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Perkins J. Chemistry courses, the Parisian chemical world and the chemical revolution, 1770-1790. Ambix 2010; 57:27-47. [PMID: 20533813 DOI: 10.1179/174582310x12629173849926] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
The last two decades of the ancien régime saw a rapid growth in the number of chemistry courses being offered in Paris. These courses were central to the continuing popularisation of chemistry, but they played an equally important role in the development of a large and dynamic community of chemical practitioners in Paris. They indicate that this community was undergoing major changes: rapid growth that challenged the position and authority of the Académie; expanding opportunities for making a career in and around the teaching of chemistry; new ways of organising research; a change in the relationship between pharmacy and chemistry; and the emergence of new forms of scientific sociability. These developments pre-date the chemical and political revolutions, and provide the context for a broader understanding of both the Chemical Revolution and the politically contested history of chemistry during the Revolution and Empire.
Collapse
Affiliation(s)
- John Perkins
- Centre for Health, Medicine and Society, Oxford Brookes University, UK.
| |
Collapse
|